F. Marques, Alysson Luiz Mendes da Silva, R. Mattoso, Roque Aras Júnior, Rogério Jorge B. de Oliveira, Júlio Cezar de Abreu Santos, F. D. Couto, R. Couto
{"title":"Low-Flow Polysulfone Hemodialysis Alters Lipoprotein Parameters, Paraoxonase Activity and in Vitro Incorporation of Phospholipids","authors":"F. Marques, Alysson Luiz Mendes da Silva, R. Mattoso, Roque Aras Júnior, Rogério Jorge B. de Oliveira, Júlio Cezar de Abreu Santos, F. D. Couto, R. Couto","doi":"10.4236/JBPC.2017.83003","DOIUrl":null,"url":null,"abstract":"End stage-renal-disease (ESRD) is associated with dyslipidemia and premature atherosclerosis. The study evaluates the effect of hemodialysis (HD) on HDL-remodeling between pre- and post-HD. Was conducted a cross-sectional study with 50 ESRD male patients, undergoing HD at Ana Neri Hospital, Salvador, Brazil. All individuals were on HD for at least 3 months, into a three sessions protocol for 3 - 4 hours per week, with a polysulfone low-flow basic-dialyzing-membrane and unfractionated-heparin. HDL Phospholipid-incorporation was measured by 14C-PL-scintillation-counting, expressed as %14C-PL/mL/hour. Paraoxonase (PON-1) activity was measured by spectrophotometry using paraoxon as substrate. Cardiovascular risk ratios and atherogenic index of plasma were calculated. Total cholesterol, HDL-C and non-HDL-C increased at post-HD on all age groups, but without triglycerides (TG) changes. TG/HDL-C decreased in 30 - 39 and 40 - 49 year (y) at post-HD (p 60 y, after HD (p 60 (p 60 y, at post-HD (p 60 y, both at pre- (r = 0.63; p = 0.029) and post-HD (r = 0.65; p = 0.022). PON-1 activity increased at pre- (59 ± 30) and post-HD (73 ± 38) in 50 - 59 y (p 60 y (p < 0.05), when compared to pre- and post-HD. ESRD patients undergoing HD shows important changes on lipid-profile, PON-1-activity, cardiac risk ratios and HDL-remodeling. These results demonstrate the influence of HD with a polysulfone low-flow basic-dialyzing-membrane and unfractionated-heparin on lipoprotein metabolism.","PeriodicalId":62927,"journal":{"name":"生物物理化学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"生物物理化学(英文)","FirstCategoryId":"1089","ListUrlMain":"https://doi.org/10.4236/JBPC.2017.83003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
End stage-renal-disease (ESRD) is associated with dyslipidemia and premature atherosclerosis. The study evaluates the effect of hemodialysis (HD) on HDL-remodeling between pre- and post-HD. Was conducted a cross-sectional study with 50 ESRD male patients, undergoing HD at Ana Neri Hospital, Salvador, Brazil. All individuals were on HD for at least 3 months, into a three sessions protocol for 3 - 4 hours per week, with a polysulfone low-flow basic-dialyzing-membrane and unfractionated-heparin. HDL Phospholipid-incorporation was measured by 14C-PL-scintillation-counting, expressed as %14C-PL/mL/hour. Paraoxonase (PON-1) activity was measured by spectrophotometry using paraoxon as substrate. Cardiovascular risk ratios and atherogenic index of plasma were calculated. Total cholesterol, HDL-C and non-HDL-C increased at post-HD on all age groups, but without triglycerides (TG) changes. TG/HDL-C decreased in 30 - 39 and 40 - 49 year (y) at post-HD (p 60 y, after HD (p 60 (p 60 y, at post-HD (p 60 y, both at pre- (r = 0.63; p = 0.029) and post-HD (r = 0.65; p = 0.022). PON-1 activity increased at pre- (59 ± 30) and post-HD (73 ± 38) in 50 - 59 y (p 60 y (p < 0.05), when compared to pre- and post-HD. ESRD patients undergoing HD shows important changes on lipid-profile, PON-1-activity, cardiac risk ratios and HDL-remodeling. These results demonstrate the influence of HD with a polysulfone low-flow basic-dialyzing-membrane and unfractionated-heparin on lipoprotein metabolism.